# Axsome Therapeutics, Inc. (AXSM) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Axsome Therapeutics, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/AXSM/mda/fy2025/): filed 2026-02-23; accession 0001193125-26-064267 (https://www.sec.gov/Archives/edgar/data/1579428/000119312526064267/axsm-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/AXSM/mda/fy2024/): filed 2025-02-18; accession 0000950170-25-022457 (https://www.sec.gov/Archives/edgar/data/1579428/000095017025022457/axsm-20241231.htm)
- [FY 2023 MD&A](/company/AXSM/mda/fy2023/): filed 2024-02-23; accession 0000950170-24-019118 (https://www.sec.gov/Archives/edgar/data/1579428/000095017024019118/axsm-20231231.htm)
- [FY 2022 MD&A](/company/AXSM/mda/fy2022/): filed 2023-02-28; accession 0000950170-23-004728 (https://www.sec.gov/Archives/edgar/data/1579428/000095017023004728/axsm-20221231.htm)
- [FY 2021 MD&A](/company/AXSM/mda/fy2021/): filed 2022-03-01; accession 0000950170-22-002568 (https://www.sec.gov/Archives/edgar/data/1579428/000095017022002568/axsm-20211231.htm)

Back to /company/AXSM/